Vectura: VR315 US development milestone (BUY) | Akers Biosciences*: EMEA distribution agreements (CORP) | Lok’nStore*: Extracting maximum value (CORP)| Staffline: Analyst interview (BUY)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Morning Note
- Published:
01 Oct 2015 -
Author:
Guy Hewett | Cavendish Research - Pages:
Vectura: VR315 US development milestone (BUY) | Akers Biosciences*: EMEA distribution agreements (CORP) | Lok’nStore*: Extracting maximum value (CORP)| Staffline: Analyst interview (BUY)